Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 5/20 | 0.57 |
| ▸ | NAMPT | P43490 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618589 | 0.91 | TTK (0.58) | TTKNAMPTNPC1 | |
| SCHEMBL5619038 | 0.91 | TTK (0.57) | TTKNAMPTRAB9ANPC1POLB | |
| SCHEMBL5618516 | 0.90 | TTK (0.59) | TTKNAMPT | |
| SCHEMBL5619165 | 0.89 | TTK (0.55) | TTKNAMPTRAB9ANPC1POLB | |
| SCHEMBL5619180 | 0.85 | MAPKAPK5 (0.57) | TTKNAMPT | |
| SCHEMBL5618496 | 0.84 | TTK (0.54) | TTK | |
| SCHEMBL5619090 | 0.84 | TTK (0.54) | TTKNAMPTEPHX2 | |
| SCHEMBL5618750 | 0.83 | TTK (0.62) | TTK | |
| SCHEMBL5618424 | 0.83 | TTK (0.57) | TTKRAB9ANPC1 | |
| SCHEMBL5618058 | 0.83 | TTK (0.53) | TTKNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | claimed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | TTK 69/4885NAMPT 1256/4885RAB9A 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.